中信建投:繼續看好創新藥和高壁壘仿製藥
中信建投研報表示,國家醫保局堅持集採與醫保談判常態化推進、促進醫保基金“騰籠換鳥”的同時,在集採端優化品種遴選以及報量、競價規則,有助於科學引導企業從“低價競爭”往“質量競爭+成本控制+合理利潤”的方向轉變,進而促進國內仿製藥市場生態圈健康發展,更大程度上保障人民羣眾的用藥需求。看好具有嚴格質量體系、具有規模成本優勢、獲得臨牀認可和廣泛使用的產品在集採中維持甚至擴大市場份額。另一方面,創新藥持續獲得政策支持,2024年醫保談判中創新藥成功率超90%,國產佔比達70%以上,商保政策陸續出台,為創新藥支付端提供增量可能;《支持創新藥高質量發展的若干措施》對創新藥從研發到支付全過程進行頂層設計。同時國內創新藥企業國際化競爭力持續提升,新技術推動行業快速發展,未來繼續看好相關創新藥及製藥企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.